LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 266

Search options

  1. Book ; Conference proceedings: From targets to therapy: novel drugs in advanced clinical trials

    Aghajanian, Carol / Armitage, James O.

    [based on the proceedings of a CME certified satellite symposium held at ASCO 2003]

    (Seminars in oncology ; 31,6, Suppl. 16)

    2004  

    Author's details James O. Armitage ... guest ed. Contributors Carol Aghajanian
    Series title Seminars in oncology ; 31,6, Suppl. 16
    Collection
    Language English
    Size 38 S. : Ill., graph. Darst.
    Publisher Saunders
    Publishing place Philadelphia, PA
    Publishing country United States
    Document type Book ; Conference proceedings
    HBZ-ID HT014299698
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 1348 -31,Suppl.16- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book ; Conference proceedings: The Fox Chase Cancer Center investigators' workshop and consensus conference

    Aghajanian, Carol / Ozols, Robert F.

    [March 4 - 6, 1999, Lana'i, Hawaii]

    (Seminars in oncology ; 26,6, Suppl. 18)

    1999  

    Institution Fox Chase Cancer Center
    Author's details Robert F. Ozols, guest ed. Contrib.: Carol Aghajanian
    Series title Seminars in oncology ; 26,6, Suppl. 18
    Collection
    Language English
    Size 76 S.
    Publisher Saunders
    Publishing place Philadelphia, PA
    Publishing country United States
    Document type Book ; Conference proceedings
    HBZ-ID HT011171257
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 1348 -26,6,Suppl.18- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Response to Letter to the Editor, Gilks et al.

    Weigelt, Britta / Mueller, Jennifer J / Ellenson, Lora H / Abu-Rustum, Nadeem R / Aghajanian, Carol

    Gynecologic oncology

    2023  Volume 176, Page(s) 181–182

    Language English
    Publishing date 2023-07-10
    Publishing country United States
    Document type Letter
    ZDB-ID 801461-9
    ISSN 1095-6859 ; 0090-8258
    ISSN (online) 1095-6859
    ISSN 0090-8258
    DOI 10.1016/j.ygyno.2023.07.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 885: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Treatment of low-risk gestational trophoblastic neoplasia.

    Aghajanian, Carol

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2011  Volume 29, Issue 7, Page(s) 786–788

    MeSH term(s) Choriocarcinoma/drug therapy ; Choriocarcinoma/pathology ; Dactinomycin/administration & dosage ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Gestational Trophoblastic Disease/drug therapy ; Gestational Trophoblastic Disease/pathology ; Humans ; Methotrexate/administration & dosage ; Neoplasm Staging ; Pregnancy ; Pulse Therapy, Drug ; Risk Assessment ; Treatment Outcome
    Chemical Substances Dactinomycin (1CC1JFE158) ; Methotrexate (YL5FZ2Y5U1)
    Language English
    Publishing date 2011-03-01
    Publishing country United States
    Document type Clinical Trial, Phase III ; Comment ; Editorial ; Randomized Controlled Trial
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2010.31.0151
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes.

    Praiss, Aaron M / White, Charlie / Iasonos, Alexia / Selenica, Pier / Zivanovic, Oliver / Chi, Dennis S / Abu-Rustum, Nadeem R / Weigelt, Britta / Aghajanian, Carol / Girshman, Jeffrey / Park, Kay J / Grisham, Rachel N

    Gynecologic oncology

    2024  Volume 182, Page(s) 32–38

    Abstract: Objectives: Mesonephric (MA) and mesonephric-like (MLA) adenocarcinomas are rare cancers, and data on clinical behavior and response to therapy are limited. We sought to report molecular features, treatment, and outcomes of MA/MLA from a single ... ...

    Abstract Objectives: Mesonephric (MA) and mesonephric-like (MLA) adenocarcinomas are rare cancers, and data on clinical behavior and response to therapy are limited. We sought to report molecular features, treatment, and outcomes of MA/MLA from a single institution.
    Methods: Patients with MA (cervix) or MLA (uterus, ovary, other) treated at Memorial Sloan Kettering Cancer Center (MSK) from 1/2008-12/2021 underwent pathologic re-review. For patients with initial treatment at MSK, progression-free survival (PFS1) was calculated as time from initial surgery to progression or death; second PFS (PFS2) was calculated as time from start of treatment for recurrence to subsequent progression or death. Overall survival (OS) was calculated for all patients. Images were retrospectively reviewed to determine treatment response. Somatic genetic alterations were assessed by clinical tumor-normal sequencing (MSK-Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]).
    Results: Of 81 patients with confirmed gynecologic MA/MLA, 36 received initial treatment at MSK. Sites of origin included cervix (n = 9, 11%), uterus (n = 42, 52%), ovary (n = 28, 35%), and other (n = 2, 2%). Of the 36 patients who received initial treatment at MSK, 20 (56%) recurred; median PFS1 was 33 months (95% CI: 17-not evaluable), median PFS2 was 8.3 months (95% CI: 6.9-14), and median OS was 87 months (95% CI: 58.2-not evaluable). Twenty-six of the 36 patients underwent MSK-IMPACT testing, and 25 (96%) harbored MAPK pathway alterations.
    Conclusion: Most patients diagnosed with early-stage disease ultimately recurred. Somatic MAPK signaling pathway mutations appear to be highly prevalent in MA/MLA, and therapeutics that target this pathway are worthy of further study.
    MeSH term(s) Humans ; Female ; Retrospective Studies ; Adenocarcinoma/genetics ; Adenocarcinoma/therapy ; Adenocarcinoma/pathology ; Mutation ; Ovary/pathology ; Cervix Uteri/pathology
    Language English
    Publishing date 2024-01-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 801461-9
    ISSN 1095-6859 ; 0090-8258
    ISSN (online) 1095-6859
    ISSN 0090-8258
    DOI 10.1016/j.ygyno.2024.01.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 885: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).

    Lumish, Melissa / Chui, M Herman / Zhou, Qin / Iasonos, Alexia / Sarasohn, Debra / Cohen, Seth / Friedman, Claire / Grisham, Rachel / Konner, Jason / Kyi, Chrisann / Rubinstein, Maria / Troso-Sandoval, Tiffany / Aghajanian, Carol / Makker, Vicky

    Gynecologic oncology

    2024  Volume 182, Page(s) 75–81

    Abstract: Objective: HER2 overexpression is associated with decreased overall survival in metastatic endometrial cancer. Trastuzumab with chemotherapy has demonstrated efficacy for first-line management of advanced HER2+ endometrial carcinoma, but HER2-directed ... ...

    Abstract Objective: HER2 overexpression is associated with decreased overall survival in metastatic endometrial cancer. Trastuzumab with chemotherapy has demonstrated efficacy for first-line management of advanced HER2+ endometrial carcinoma, but HER2-directed therapy in the recurrent setting is limited. Zanidatamab (ZW25), a humanized, bispecific antibody that simultaneously binds the 2 distinct HER2 epitopes bound by trastuzumab and pertuzumab, has demonstrated safety and activity in HER2+ tumors. Here, we report the results of a phase 2, open-label study evaluating the efficacy and safety of zanidatamab in patients with HER2+ metastatic endometrial carcinoma/carcinosarcoma who received prior treatment.
    Methods: We enrolled 16 patients with HER2+ endometrial carcinoma/carcinosarcoma after progression on ≤2 lines of therapy on a single-arm phase 2 study of zanidatamab. The primary endpoint was overall response rate (ORR; complete or partial response) by Response Evaluation Criteria in Solid Tumors version 1.1. HER2 immunohistochemistry and fluorescence in situ hybridization (FISH) were performed on pretreatment samples. Intratumor HER2 genetic heterogeneity was assessed.
    Results: This study did not meet its primary efficacy endpoint. Although a clinical benefit rate of 37.5% was observed by 24 weeks, only 1 patient achieved a partial response (ORR, 6.2%). Eight patients had HER2 intratumor heterogeneity or lacked HER2 amplification by FISH. Decreased HER2 expression on repeat pretreatment samples was observed in 3 (75%) of 4 patients evaluated.
    Conclusions: We observed a low response rate to zanidatamab in recurrent HER2+ endometrial carcinoma/carcinosarcoma, which may be driven by downregulation of HER2 expression. Repeat HER2 testing should be considered prior to second-line HER2-directed therapy.
    Clinicaltrials: govidentifier: NCT04513665.
    MeSH term(s) Female ; Humans ; Receptor, ErbB-2/metabolism ; In Situ Hybridization, Fluorescence ; Neoplasm Recurrence, Local/pathology ; Trastuzumab ; Endometrial Neoplasms/drug therapy ; Endometrial Neoplasms/genetics ; Endometrial Neoplasms/pathology ; Carcinosarcoma/drug therapy ; Carcinosarcoma/genetics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antibodies, Bispecific
    Chemical Substances zanidatamab ; Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK) ; Antibodies, Bispecific
    Language English
    Publishing date 2024-01-22
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article
    ZDB-ID 801461-9
    ISSN 1095-6859 ; 0090-8258
    ISSN (online) 1095-6859
    ISSN 0090-8258
    DOI 10.1016/j.ygyno.2023.12.028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 885: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.

    Makker, Vicky / Taylor, Matthew H / Aghajanian, Carol / Cohn, Allen L / Brose, Marcia S / Simone, Christopher Di / Cao, Zhu Alexander / Suttner, Leah / Loboda, Andrey / Cristescu, Razvan / Jelinic, Petar / Orlowski, Robert / Dutta, Lea / Matsui, Junji / Dutcus, Corina E / Minoshima, Yukinori / Messing, Mark J

    Journal for immunotherapy of cancer

    2024  Volume 12, Issue 1

    Abstract: Background: Lenvatinib plus pembrolizumab demonstrated clinically meaningful benefit in patients with previously treated advanced endometrial carcinoma in Study 111/KEYNOTE-146 (NCT02501096). In these exploratory analyses from this study, we evaluated ... ...

    Abstract Background: Lenvatinib plus pembrolizumab demonstrated clinically meaningful benefit in patients with previously treated advanced endometrial carcinoma in Study 111/KEYNOTE-146 (NCT02501096). In these exploratory analyses from this study, we evaluated the associations between clinical outcomes and gene expression signature scores and descriptively summarized response in biomarker subpopulations defined by tumor mutational burden (TMB) and DNA variants for individual genes of interest.
    Methods: Patients with histologically confirmed metastatic endometrial carcinoma received oral lenvatinib 20 mg once daily plus intravenous pembrolizumab 200 mg every 3 weeks for 35 cycles. Archived formalin-fixed paraffin-embedded tissue was obtained from all patients. T-cell-inflamed gene expression profile (Tcell
    Results: 93 and 79 patients were included in the RNA-sequencing-evaluable and WES-evaluable populations, respectively. No statistically significant associations were observed between any of the RNA-sequencing signature scores and objective response rate or progression-free survival. Area under the receiver operating characteristic curve values for response ranged from 0.39 to 0.54; all 95% CIs included 0.50. Responses were seen regardless of TMB (≥175 or <175 mutations/exome) and mutation status. There were no correlations between Tcell
    Conclusions: This analysis demonstrated efficacy for lenvatinib plus pembrolizumab regardless of biomarker status. Results from this study do not support clinical utility of the evaluated biomarkers. Further investigation of biomarkers for this regimen is warranted.
    Trial registration number: NCT02501096.
    MeSH term(s) Female ; Humans ; Endometrial Neoplasms/drug therapy ; Endometrial Neoplasms/genetics ; Biomarkers, Tumor/genetics ; RNA/therapeutic use ; Phenylurea Compounds ; Quinolines ; Antibodies, Monoclonal, Humanized
    Chemical Substances pembrolizumab (DPT0O3T46P) ; lenvatinib (EE083865G2) ; Biomarkers, Tumor ; RNA (63231-63-0) ; Phenylurea Compounds ; Quinolines ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2024-01-19
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2023-007929
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.

    Gien, Lilian T / Enserro, Danielle M / Block, Matthew S / Waggoner, Steven / Duska, Linda R / Wahner-Hendrickson, Andrea E / Thaker, Premal H / Backes, Floor / Kidd, Michael / Muller, Carolyn Y / DiSilvestro, Paul A / Covens, Allan / Gershenson, David M / Moore, Kathleen N / Aghajanian, Carol / Coleman, Robert L

    Gynecologic oncology

    2024  Volume 186, Page(s) 61–68

    Abstract: Introduction: Early reports of PD-1 inhibition in ovarian clear cell carcinomas (OCCC) demonstrate promising response. We evaluated the combination of pembrolizumab and IDO-1 inhibitor epacadostat in patients with recurrent OCCC.: Methods: This ... ...

    Abstract Introduction: Early reports of PD-1 inhibition in ovarian clear cell carcinomas (OCCC) demonstrate promising response. We evaluated the combination of pembrolizumab and IDO-1 inhibitor epacadostat in patients with recurrent OCCC.
    Methods: This single arm, two-stage, phase 2 trial included those with measurable disease and 1-3 prior regimens. Patients received intravenous pembrolizumab 200 mg every 3 weeks and oral epacadostat 100 mg twice a day. Primary endpoint was overall response rate (ORR), secondary endpoints were toxicity, progression-free survival (PFS) and overall survival (OS). The study was powered to detect an absolute 25% increase in response (15% to 40%).
    Results: Between September 28, 2018 and April 10, 2019, 14 patients enrolled at first stage. Rate of accrual was 2.3 patients per month. Median age was 65 years (44-89), 10 (71.4%) had ≥2 prior regimens. ORR was 21% (95% CI 5-51%) within 7 months of study entry with 3 partial responses, and 4 had stable disease (disease control rate 50%). Median PFS was 4.8 months (95% CI: 1.9-9.6), OS 18.9 months (95% CI: 1.9-NR). Most common grade ≥ 3 adverse events were electrolyte abnormalities and gastrointestinal pain, nausea, vomiting, bowel obstruction. In July 2019, the study reached the pre-specified criteria to re-open to second stage; however, the study closed prematurely in February 2021 due to insufficient drug supply.
    Conclusions: Pembrolizumab and epacadostat demonstrated an ORR of 21% in this small cohort of recurrent OCCC. The rapid rate of accrual highlights the enthusiasm and need for therapeutic studies in patients with OCCC.
    Language English
    Publishing date 2024-04-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 801461-9
    ISSN 1095-6859 ; 0090-8258
    ISSN (online) 1095-6859
    ISSN 0090-8258
    DOI 10.1016/j.ygyno.2024.03.027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 885: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: The role of bevacizumab in ovarian cancer--an evolving story.

    Aghajanian, Carol

    Gynecologic oncology

    2006  Volume 102, Issue 2, Page(s) 131–133

    MeSH term(s) Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab ; Carboplatin/administration & dosage ; Clinical Trials as Topic ; Combined Modality Therapy ; Female ; Humans ; Ovarian Neoplasms/therapy ; Paclitaxel/administration & dosage ; Randomized Controlled Trials as Topic
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Bevacizumab (2S9ZZM9Q9V) ; Carboplatin (BG3F62OND5) ; Paclitaxel (P88XT4IS4D)
    Language English
    Publishing date 2006-08
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 801461-9
    ISSN 1095-6859 ; 0090-8258
    ISSN (online) 1095-6859
    ISSN 0090-8258
    DOI 10.1016/j.ygyno.2006.06.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 885: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Impact of Provider Imaging Practices on Survival Outcomes in Advanced Ovarian Cancer.

    Green, Angela K / Korenstein, Deborah / Aghajanian, Carol / Barrow, Brooke / Curry, Michael / O'Cearbhaill, Roisin E

    Journal of the National Comprehensive Cancer Network : JNCCN

    2020  Volume 18, Issue 4, Page(s) 414–419

    Abstract: Background: This study sought to describe how high- versus low-frequency surveillance imaging practices among providers at Memorial Sloan Kettering Cancer Center (MSKCC) impact overall survival (OS) and time to recurrence of patients with advanced ... ...

    Abstract Background: This study sought to describe how high- versus low-frequency surveillance imaging practices among providers at Memorial Sloan Kettering Cancer Center (MSKCC) impact overall survival (OS) and time to recurrence of patients with advanced epithelial ovarian cancer in first remission.
    Methods: The study cohort included patients with stage II-IV high-grade epithelial ovarian cancer diagnosed in January 2001 through January 2017 who experienced recurrence after initial platinum-based chemotherapy. To determine usual imaging practices for providers at MSKCC, median frequency of CT or MRI of the abdomen/pelvis was calculated among patients with a long-term remission (defined as at least 1 year) treated by each provider. Cox proportional hazards models were used to examine differences in OS and time to recurrence among patients treated by providers with high versus low imaging frequency practices, with additional subgroup analysis among patients with elevated CA-125 levels >35 U/mL at diagnosis. Chi-square tests were used to examine differences in the proportion of patients who enrolled in clinical trials or underwent secondary cytoreductive surgery (SCS) by imaging frequency.
    Results: A total of 543 patients were treated by providers with high imaging frequency (>1 scan every 12 months) and 141 were treated by providers with low imaging frequency (≤1 scan every 12 months). Time to recurrence was shorter among patients treated by providers with high versus low imaging frequency (18.0 vs 19.2 months; hazard ratio, 1.33; P=.003). Results were similar when restricted to patients with elevated CA-125 levels at diagnosis. There was no significant difference in OS, clinical trial enrollment, or SCS by imaging practice.
    Conclusions: Within the limitations of this retrospective analysis, patients with advanced ovarian cancer treated by high-frequency-imaging providers had earlier detection of recurrence. Future analyses in a larger population are warranted to elucidate the risks versus benefits of surveillance imaging.
    MeSH term(s) Adult ; Aged ; Biomarkers, Tumor ; Diagnostic Imaging/methods ; Disease Management ; Female ; Health Impact Assessment ; Health Personnel ; Humans ; Middle Aged ; Neoplasm Grading ; Neoplasm Metastasis ; Neoplasm Staging ; Outcome Assessment, Health Care ; Ovarian Neoplasms/diagnosis ; Ovarian Neoplasms/epidemiology ; Ovarian Neoplasms/mortality ; Practice Patterns, Physicians' ; Prognosis ; Public Health Surveillance
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2020-04-04
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2250759-0
    ISSN 1540-1413 ; 1540-1405
    ISSN (online) 1540-1413
    ISSN 1540-1405
    DOI 10.6004/jnccn.2019.7376
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6365: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top